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OBJECTIVES: Poor adherence to antihypertensive regi-
mens has frequently been cited as a factor for failing to
achieve blood pressure goals in patients with hyperten-
sion. The objective of our study was to determine factors
associated with adherence to antihypertensive regimens in
members enrolled in a commercial managed care organi-
zation (MCO). METHODS: All members evaluated 
had a diagnosis of hypertension and were continuously
enrolled during the one-year study period. Severity of
illness was stratiﬁed by co-existing medical complications
associated with hypertension. Members receiving one or
more antihypertensive medications were the population
evaluated in our retrospective analysis. Average medica-
tion possession ratio (MPR) on all antihypertensive med-
ications was used as the primary adherence indicator in
this study. Factors evaluated included member age,
gender, severity of illness, number of concurrent antihy-
pertensive medications, dosing schedule, and sum of total
days supply of medication. Variable were evaluated using
a forward step-wise regression analysis. RESULTS: There
were 3306 members identiﬁed with hypertension in 
the MCO. MPR was evaluated in 2116 members on an-
tihypertensive medications. The mean age was 52.2 years
and 47% were female. The most common classes of anti-
hypertensive medications utilized were Calcium Channel
Blockers, ACE Inhibitors, and Diuretics. The regression
model for average MPR was signiﬁcant (F = 127.72, 
p < 0.001). Factors signiﬁcantly correlated with average
MPR were total days supply (b = 0.73, p < 0.001), age
(b = 0.08, p < 0.001), number of current medications 
(b = -.057, p < 0.001) and dosing schedule (b = 0.08, 
p < 0.001). CONCLUSIONS: A number of factors were
found to be signiﬁcant predictors of adherence to antihy-
pertensive medications. Members that were older and
received the drugs for longer periods of time had better
adherence. Adherence to medication tended to decrease
as the number of concurrent medications increased and
as the number of doses of medication taken per day
increased. Disease severity and gender were not found to
be signiﬁcant predictors of adherence.
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OBJECTIVE: The objective of this study was to evaluate
the effects of various statin doses on the attainment of
target LDL-Cholesterol (LDL-C) levels in clinical prac-
tice. METHODS: Patients newly initiated on atorvas-
tatin, ﬂuvastatin, pravastatin, or simvastatin from 1/99 to
6/99 were retrospectively identiﬁed from a southeastern
U.S. health plan database. Exclusion criteria included
statin therapy in the prior 6 months, less than 90 days of
statin therapy, switching of statin, use of combination
dyslipidemia therapy, and less than 18 months of contin-
uous plan enrollment. For each statin dose, attainment 
of target LDL-C based on NCEP ATP II guidelines was 
analyzed using univariate (unadjusted) and multivariate
(adjusted) logistic regression. Covariates utilized in the
adjusted analysis were age, gender, presence of athero-
sclerotic vascular disease, and difference between baseline
and target LDL-C. RESULTS: A total of 1938 statin dose
episodes from 1645 eligible patients (mean age = 66.3 ±
10.4 years, 47% male) were evaluated. Mean absolute
(percent) LDL-C reductions across statin dose ranges
were: atorvastatin [67–81mg/dL (39–43%)], ﬂuvastatin
[34–42mg/dL (21–26%)], pravastatin [39–45mg/dL
(24–26%)], and simvastatin [52–67mg/dL (32–38%)]. In
the unadjusted results, atorvastatin 20mg, ﬂuvastatin 
20mg and 40mg, pravastatin 20mg and 40mg, and sim-
vastatin 10mg had signiﬁcantly lower odds of attaining
NCEP II LDL-C target when compared to atorvastatin 
10mg. In the adjusted results, ﬂuvastatin 20mg and 
40mg, pravastatin 20mg and 40mg, and simvastatin 
10mg and 20mg had signiﬁcantly lower odds of attain-
ing NCEP II LDL-C target as compared to atorvastatin
10mg. CONCLUSIONS: Patients prescribed atorvastatin
10mg had greater odds of attaining their target LDL-C
level than patients prescribed all other statin doses in the
adjusted analysis except for simvastatin 40mg and ator-
vastatin 20mg.
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OBJECTIVES: To examine the clinical effectiveness of
amlodipine as monotherapy or in combination with other
antihypertensives in systolic blood pressure (SBP) control
and JNC IV goal attainment within a multi-center ambu-
latory care setting. METHODS: Hypertensive adults were
identiﬁed over a 4-year period (1998–2001) from a large
commercially available electronic medical record (EMR)
database covering over 360,000 US primary care patients.
Study patients were required to have initiated therapy
with amlodipine and have at least one BP measurement
within 6 months prior to and 12 months following the
index date. Those with a documented diagnosis of CHF
or prior use of calcium channel blockers were excluded.
Mean change in SBP was compared using multivariable
regression, controlling for differences in age, gender,
comorbid conditions, baseline SBP, and days between
beginning and ending BP reading. Incremental rates of
JNC VI goal attainment are also presented. RESULTS:
One thousand one hundred seventy-ﬁve patients were
identiﬁed. Mean baseline SBP was 159.5mmHg (SD:
19.5). Adjusted SBP reductions in mmHg (%) were 16.0
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(10.3%) for amlodipine alone, and 17.5 (10.9%), 17.0
(10.4%), and 15.8 (9.7%) for amlodipine in combin-
ation with 1, 2, or 3 additional medications, respectively.
Observed differences of JNC VI goal attainment were
40%, 45%, 42%, and 45%, respectively. Amlodipine ini-
tiation in all regimens showed statistically signiﬁcant SBP
reduction & goal attainment from baseline (p < 0.001).
CONCLUSIONS: Patients receiving amlodipine as
monotherapy or in combination with other agents had
statistically signiﬁcant and clinically meaningful improve-
ments in SBP outcomes and in JNC VI goal attainment
within 12-months of initiating treatment. Although 
these data must be interpreted within the limitations of
the observational study design, this study suggests that
amlodipine may be used in a variety of therapeutic com-
binations to improve SBP goal attainment among hyper-
tensive adults.
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Pulmonary arterial hypertension (PAH) is a rare, incur-
able and often fatal disorder. Current management
includes conventional therapy, prostacyclin therapy for
more advanced patients, and newer agents such as bosen-
tan, an endothelin antagonist. To date, no systematic
review has assessed these interventions. OBJECTIVE: To
perform a systematic review of the medical interventions
used in the management of PAH. METHODS: A litera-
ture search of EMBASE and MEDLINE was performed
in April 2002 and in November 2002. Data for three
outcome measures; survival, exercise capacity, and right
atrial pressure were extracted. Where possible, data were
segregated according to intervention, the type of PAH and
the NYHA/WHO functional class of patients evaluated
in the studies. RESULTS: The literature search yielded
1503 abstracts. 54 papers were included after ﬁrst pass
assessment. Following second pass assessment 28 papers
were included, and were extracted. An additional four
studies were identiﬁed after running the second literature
search. Three studies met second pass inclusion criteria
and were included in the analysis. Three-year survival
rates were 47% to 76% across all interventions. Mean
changes in right atrial pressure from baseline ranged from
a reduction of 6mmHg with epoprostenol to an increase
of 2mmHg with aerosolised iloprost. Mean changes in
exercise capacity from baseline varied from an increase
of 10m with trepostinil in combination with conventional
therapy to an increase of 142m with epoprostenol. The
endothelin-receptor antagonist, bosentan, was found to
have signiﬁcant beneﬁcial effects on exercise capacity,
right atrial pressure superior to iloprost and in certain
instances comparable to epoprostenol. CONCLUSION:
Quantitative comparisons of the interventions are difﬁ-
cult within the context of this review, but the homogene-
ity of the data may make meta-analysis of the evidence
possible in certain circumstances. To make the most valu-
able comparison, long-term data is needed, in particular
assessing mortality.
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OBJECTIVE: Treatment of PPH considers four func-
tional classes. All classes can be managed by medical
therapy. However, recalcitrant class III and IV patients 
are managed by lung transplantation. This study com-
pares the cost-utility of these treatment modalities.
METHODS: Decision modeling is used to evaluate a cost-
utility of treatment modalities for PPH. From 2000 to
2002, 139 patients were evaluated for pulmonary hyper-
tension (PH) at OSU HLRI. Thirty-nine had PPH, 34 had
secondary PH, and the remainder was negative for PH.
Concentrating on the PPH population, 2 died without
treatment, 1 was not interested in treatment, 2 were func-
tional class III/IV and were evaluated for lung transplan-
tation, 12 were started on Flolan, and the rest on Tracleer
and Flolan/Tracleer combination. Probabilities for 
treatment modality choice were calculated based on 
these numbers. Life expectancy and utilities for patients
on Flolan, Tracleer and lung transplant recipients were
obtained from prior studies. Given the probabilities, life
expectancy and utilities, QALYs were calculated as Prob-
ability X Utility X Life Expectancy. The costs for therapy
were annual direct cost for Flolan ($70,000–100,000),
Tracleer ($100/day) and Transplantation ($150,000–
250,000, surgery alone). For simplicity, no other costs
were considered. RESULTS: Patients on Flolan alone had
1.16 QALYs, those on Tracleer or Tracleer/Flolan com-
bination had 2.6 QALYs. On Average, medical therapy
yields 1.88 QALYs. Reported QALYs for all lung trans-
plant recipients is 5.2. Cost/QALY for Flolan ranges
$60,344–86,206; that for Tracleer $14,038; Tracleer/
Flolan combination $26,250; and for lung transplanta-
tion, $61,000 follow-up cost/QALY gained, reported for
Netherlands lung transplantation studies. CONCLU-
SIONS: Tracleer is an orally active endothelin receptor
antagonist that is promising in the treatment for PPH. Its
associated low Cost/QALY makes it attractive over Flolan
alone or lung transplantation. Early diagnosis of PPH and
its treatment by Tracleer and Tracleer/Flolan combination
is cost saving and promising.
